Amgen submitted a supplemental New Drug Application to the FDA for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The sNDA is based on data from the global ENDEAVOR trial. ENDEAVOR is the first of two head-to-head...
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
